After the FDA posted briefing documents ahead of its Allergenic Products Advisory Committee Meeting on September 13 to review Aimmune Therapeutics' peanut allergen powder, Palforzia, Stifel analyst Derek Archila said the documents "seem pretty benign" and did not generate any new issues. He expects the focus of the Adcom to be on safety, which is not "new" news, and thinks the document release should provide some relief for shares given that the "worst case" scenario in terms of the panel may be off the table. He sees the risk/reward as less favorable once Palforzia is approved given the commercial/logistical challenges he sees ahead, added Archila, who keeps a Hold rating on Aimmune shares.